Sino Biological/VEGF165蛋白，人/食蟹猴，重组/1/11066-HNAB
商品编号：
11066-HNAB
品牌：
sinobiological
市场价：
¥0.00
美元价：
0.00
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
VEGF165 Protein, Human / Cynomolgus, Recombinant: Product Information
Purity
> 97 % as determined by SDS-PAGE
Endotoxin
< 1.0="" eu="" per="" μg="" of="" the="" protein="" as="" determined="" by="" the="" lal="">
Activity
Measured in a cell proliferation assay using human umbilical vein endothelial cells (HUVEC).The ED50 for this effect is typically 3-12 ng/ml.
Protein Construction
A DNA sequence encoding the human / cynomolgus VEGF165 isoform (P15692-4) (Met1-Arg191) was expressed. Human and Cynomolgus VEGF165 sequences are identical.
Accession#
P15692-4
Expressed Host
Baculovirus-Insect Cells
Species
Human, Cynomolgus
Predicted N Terminal
Ala 27
Molecule Mass
The recombinant human / cynomolgus VEGF165 consists of 165 amino acids after removal of the signal peptide and predicts a molecular mass of 19.2 kDa. Due to different glycosylation, the apparent molecular mass of human VEGF165 is approximately 20 and 22 kDa in SDS-PAGE under reducing conditions, corresponding to the monomer.
Formulation
Lyophilized from sterile 100mM Glycine, 10mM NaCl, pH 7.0Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
VEGF165 Protein, Human / Cynomolgus, Recombinant: Images
Measured in a cell proliferation assay using human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is typically 3-12 ng/ml .
VEGFA Background Information
Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) and VEGF-A, is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. It is a member of the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family and often exists as a disulfide-linked homodimer. VEGF-A protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, inhibiting apoptosis and tumor growth. VEGF-A protein is also a vasodilator that increases microvascular permeability, thus it was originally referred to as vascular permeability factor.
- Cancer Immunotherapy
- Immune Checkpoint
- Immunotherapy
- Targeted Therapy
Full Name
vascular endothelial growth factor A
Research Areas
- Cancer Drug Targets
Related Pathways
VEGF Signaling Pathway
References
- Woolard J. et al. (2004) VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 64(21): 7822-7835.
- Jia SF, et al. (2008) VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells. J Exp Ther Oncol. 7(2): 89-97.
- Cimpean AM, et al. (2008) Vascular endothelial growth factor A (VEGF A) as individual prognostic factor in invasive breast carcinoma. Rom J Morphol Embryol. 49(3): 303-8.
- Hamdollah Zadeh MA, et al. (2008) VEGF-mediated elevated intracellular calcium and angiogenesis in human microvascular endothelial cells in vitro are inhibited by dominant negative TRPC6. Microcirculation. 15(7): 605-14.
- Eisenach PA, et al. (2010) MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src. J Cell Sci. 123(Pt 23):4182-4193.
- Claesson-Welsh L (2010) Gremlin: vexing VEGF receptor agonist. Blood. 116(18):3386-7.
Human VEGFA Proteins
- VEGF165 Protein, Human, Recombinant (His & AVI Tag), Biotinylated11066-H27H-B
- VEGFA Protein, Human, Recombinant (VEGF145)16444-HNAH
- VEGF121 Protein, Human, Recombinant10008-HNAH
- VEGF121b Protein, Human, Recombinant15692-HNAH
- VEGF110 Protein, Human, Recombinant29714-HNAB
- VEGFA Protein, Human, Recombinant (VEGF121), HPLC-verifiedHPLC-10008-HNAH
- VEGF165b Protein, Human, Recombinant29656-HNAB
- VEGF121 Protein, Human, Recombinant10008-HNAB
- VEGF110 Protein, Human, Recombinant29714-HNAH
- VEGF183 Protein, Human, Recombinant10009-HNAB
Mouse VEGFA Proteins
- VEGF164 Protein, Mouse, Recombinant50159-MNAB
Rat VEGFA Proteins
- VEGF164 Protein, Rat, Recombinant80006-RNAB
Danio rerio (zebrafish) VEGFA Proteins
- VEGF165 Protein, Danio rerio (zebrafish), Recombinant63004-ZNAB
Human, Cynomolgus VEGFA Proteins
- VEGFA Protein, Human, Cynomolgus, Recombinant (VEGF165), Biotinylated11066-HNAB-B
- VEGF165 Protein, Human / Cynomolgus, Recombinant11066-HNAH
- VEGFA Protein, Human, Cynomolgus, Recombinant (VEGF165), HPLC-verifiedHPLC-11066-HNAH
Canine VEGFA Proteins
- VEGFA Protein, Canine, Recombinant (VEGF164)70004-DNAH
- Xanthatin, a novel potent inhibitor of VEGFR2 signaling, inhibits angiogenesis and tumor growth in breast cancer cellsAuthorYu, Y;Yu, J;Pei, CG;Li, YY;Tu, P;Gao, GP;Year2015JournalInt J Clin Exp Pathol.Applicationcell-basedPubMed ID: 26617743FoldedExpand
- Automating hESC differentiation with 3D printing and legacy liquid handling solutionsAuthorZluhan, E;Kelly, K;LeClair, N;Wortel, D;Moody, K;Year2016JournalMethodsXApplicationculturePubMed ID: 27872822FoldedExpand
- Oxidized low-density lipoprotein decreases VEGFR2 expression in HUVECs and impairs angiogenesisAuthorZHANG, M;JIANG, L;Year2016JournalEXPERIMENTAL AND THERAPEUTIC MEDICINEApplicationcell-basedPubMed ID: 28105106FoldedExpand
If you couldn"t find the specific citation, you can:
- Find All Citations
- Submit a CitationGet a Publication Reward
- Leave Us a Message
E.coli protein expression service
Mammalian transient protein expression service
Baculovirus-insect expression service
Stable cell line development service (CHO / HEK293)
品牌介绍
北京义翘神州科技股份有限公司（Sino Biological Inc.）是一家从事生物试剂研发、生产、销售并提供技术服务的生物科技公司，主要业务包括重组蛋白、抗体、基因和培养基等产品，以及重组蛋白、抗体的开发和生物分析检测等服务。义翘神州为全球的药品研发企业和生命科学研究机构提供高质量的生物试剂产品和高水平的技术服务。公司目前生产和销售的现货产品种类超过 4.6 万种，其中重组蛋白约 6,000 种，包括超过 3,800 种人源细胞表达重组蛋白产品，能够全面满足客户对于最接近人体天然蛋白结构和性质的重组蛋白需求；公司还能提供约 12,000 种抗体，其中单克隆抗体数量约 4,600 种，能够覆盖生命科学研究的多个领域，为分子生物学、细胞生物学、免疫学、发育生物学、干细胞研究等基础科研方向和创新药物研发提供「一站式」生物试剂产品和技术服务。义翘神州的客户涵盖大学、科研院所、医药研发企业等国内外各类生物研发单位。目前公司已经在美国、欧洲建立了子公司，已成为生物试剂行业国内领先的科技公司之一。
联络我们
